Study of the Absolute Bioavailability of BMS-626529 in Healthy Subjects Following Oral Dosing of BMS-663068 and Intravenous Dosing of BMS-626529
Latest Information Update: 06 Sep 2023
At a glance
- Drugs Fostemsavir (Primary) ; Temsavir (Primary)
- Indications HIV-1 infections
- Focus Pharmacokinetics
- Sponsors ViiV Healthcare
- 23 Jun 2016 New trial record
- 20 Jun 2016 Treatment section revised with change in number of treatment arms from two to one (revised:single oral dose of BMS-663068 will be given followed by single intravenous dose of [13C]BMS 626529)